参考文献/References:
[1]Scott RM, Smith ER. Moyamoya disease and moyamoya syndrome.N Engl J Med，2009,360(12):1226-1237.
[2]Guo DC, Papke CL, Tran-Fadulu V, et al. Mutations in smooth muscle alpha-actin (ACTA2) cause coronary artery disease, stroke, and moyamoya disease, along with thoracic aortic disease. Am J Hum Genet,2009,84(5):617-627.
[3]Research Committee on the Pathology and Treatment of Spontaneous Occlusion of the Circle of Willis, Health Labour Sciences Research Grant for Research on Measures for Infractable Diseases. Guidelines for diagnosis and treatment of moyamoya disease (Spontaneous Occlusion of the Circle of Willis). Neurol Med Chir (Tokyo),2012,52（5）:245-266.
[4]Meuwissen ME, Lequin MH, Bindels-de Heus K,et al. ACTA2 mutation with childhood cardiovascular, autonomic and brain anomalies and severe outcome. Am J Med Genet A,2013,161A(6):1376-1380.
[5]Milewicz DM, stergaard JR, Ala-Kokko LM,et al. De novo ACTA2 mutation causes a novel syndrome of multisystemic smooth muscle dysfunction. Am J Med Genet A,2010,152A(10):2437-2443.
[6]Munot P, Saunders DE, Milewicz DM, et al. A novel distinctive cerebrovascular phenotype is associated with heterozygous Arg179 ACTA2 mutations. Brain,2012,135(Pt 8):2506-2514.
[7]Moller HU, Fledelius HC, Milewicz DM,et al. Eye features in three Danish patients with multisystemic smooth muscle dysfunction syndrome. Br J Ophthalmol,2012 96(9):1227-1231.
[8]Kathiravel U, Keyser B, Hoffjan S, et al. High-density oligonucleotide-based resequencing assay for mutations causing syndromic and non-syndromic forms of thoracic aortic aneurysms and dissections. Mol Cell Probes,2013,27(2):103-108.
[9]Suzuki J, Takaku A. Cerebrovascular “moyamoya” disease. Disease showing abnormal net-like vessels in base of brain. Arch Neurol, 1969, 20（3）:288-299.
[10]Houkin K, Ito M, Sugiyama T, et al. Review of past research and current concepts on the etiology of moyamoya disease. Neurol Med Chir (Tokyo)， 2012，52(5):267-277.
[11]Liu W, Morito D, Takashima S, et al. Identification of RNF213 as a susceptibility gene for moyamoya disease and its possible role in vascular development. PLoS One,2011,6(7):e22542.
[12]Miskinyte S, Butler MG, Hervé D,et al. Loss of BRCC3 deubiquitinating enzyme leads to abnormal angiogenesis and is associated with syndromic moyamoya. Am J Hum Genet,2011,88(6):718-728.
[13]Hervé D, Philippi A, Belbouab R, et al. Loss of α1β1 soluble guanylate cyclase, the major nitric oxide receptor, leads to moyamoya and achalasia. Am J Hum Genet，2014,94(3):385-394.
[14]Wu Z, Jiang H, Zhang L,et al. Molecular analysis of RNF213 gene for moyamoya disease in the Chinese Han population. PLoS One,2012,7(10):e48179.
[15]Roder C, Peters V, Kasuya H, et al. Analysis of ACTA2 in European Moyamoya disease patients. Eur J Paediatr Neurol,2011，15(2):117-122.
[16]Shimojima K, Yamamoto T. ACTA2 is not a major disease-causing gene for moyamoya disease. J Hum Genet,2009,54(11):687-688.
[17]Hu FY, Zheng HB, Xu YM, et al. ACTA2 is not a major genetic risk gene for Chinese patients with moyamoya disease. Int J Stroke,2013,8(6):E35.